During the past decade, Kansas City Urology Care conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 10 clinical trials were completed, i.e. on average, 333.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kansas City Urology Care" #1 sponsor was "Dendreon" with 4 trials, followed by "Endo Pharmaceuticals" with 2 trials sponsored, "Ferring Pharmaceuticals" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Uromedica" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kansas City Urology Care" #1 collaborator was "Astellas Pharma Inc" with 2 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 2 trials as a collaborator, "Hoosier Cancer Research Network" with 1 trials as a collaborator, "PRA Health Sciences" with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Kansas City Urology Care" are "Prostate Cancer" (6 trials), "Bladder Cancer" (2 trials), "Cancer of the Prostate" (2 trials), "Prostatic Neoplasms" (2 trials) and "Urinary Incontinence" (2 trials). Many other conditions were trialed in "Kansas City Urology Care" in a lesser frequency.

Most popular intervention types in "Kansas City Urology Care" are "Drug" (11 trials), "Biological" (4 trials), "Device" (2 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Degarelix" (2 trials), "Enzalutamide" (2 trials), "sipuleucel-T" (2 trials) and "ACT (Adjustable Continence Therapy)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kansas City Urology Care" are 14 trials for "Male" genders, 4 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Kansas City Urology Care". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Kansas City Urology Care, 1 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Kansas City Urology Care, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".